Health
COVID-19 and metabolic disease: mechanisms and clinical management
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.
Lancet Glob Health. 2020; 8: e1003-e1017
A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19.
Sci Rep. 2021; 118562
COVID-19 in people with diabetes: understanding the reasons for worse outcomes.
Lancet Diabetes Endocrinol. 2020; 8: 782-792
Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics.
Int J Obes. 2021; 45: 1163-1169
Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies.
Diabetes Metab Syndr. 2020; 14: 809-814
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.
BMJ. 2020; 369m1985
Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis.
Diabetes Metab Syndr. 2021; 15: 813-822
Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis.
Diabetes Obes Metab. 2020; 22: 1915-1924
Global pandemics interconnected – obesity, impaired metabolic health and COVID-19.
Nat Rev Endocrinol. 2021; 17: 135-149
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.
Immunity. 2021; 54: 1578-1593
Obesity could shift severe COVID-19 disease to younger ages.
Lancet. 2020; 395: 1544-1545
Consequences of the COVID-19 pandemic for patients with metabolic diseases.
Nat Metab. 2021; 3: 289-292
COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes.
Diabetes Care. 2021; 44: 526-532
Why inequality could spread COVID-19.
Lancet Public Health. 2020; 5: e240
COVID-19: Obesity, deprivation and death.
J Glob Health. 2020; 10020389
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.
Clin Microbiol Infect. 2021; ()
Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge.
J Clin Med. 2021; 102945
Unraveling the mystery surrounding post-acute sequelae of COVID-19.
Front Immunol. 2021; 12686029
ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.
Br J Pharmacol. 2013; 169: 477-492
The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
Pharmacol Res. 2017; 125: 21-38
The renin-angiotensin-aldosterone system and coronavirus disease 2019.
Eur Cardiol. 2021; 16: e07
Practical recommendations for the management of diabetes in patients with COVID-19.
Lancet Diabetes Endocrinol. 2020; 8: 546-550
Effects of taurine on ACE, ACE2 and HSP70 expression of hypothalamic-pituitary-adrenal axis in stress-induced hypertensive rats.
Adv Exp Med Biol. 2017; 975: 871-886
SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells.
Cell Metab. 2020; 32: 1028-1040.e4
Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19.
Cell Metab. 2020; 32: 1041-1051.e6
ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection.
Clin Gastroenterol Hepatol. 2020; 18: 2128-2130.e2
SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature.
Front Endocrinol (Lausanne). 2020; 11596898
SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas.
Nat Metab. 2021; 3: 149-165
SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment.
Cell Metab. 2021; 33: 1565-1576.e5
Viral infiltration of pancreatic islets in patients with COVID-19.
Nat Commun. 2021; 123534
Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients.
Med Hypotheses. 2020; 144110271
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
J Endocrinol. 2020; 247: R45-R62
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?.
Lancet Respir Med. 2020; 8: e21
Dexamethasone in hospitalized patients with COVID-19.
N Engl J Med. 2021; 384: 693-704
Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA.
Mol Metab. 2020; 32: 160-167
A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Eur Heart J Cardiovasc Pharmacother. 2021; 7: 148-157
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.
Nat Commun. 2020; 112070
DPP-4 inhibitors and severe course of illness in patients with COVID-19.
Therapie. 2021; 76: 359-360
Therapeutic potential of metformin in COVID-19: reasoning for its protective role.
Trends Microbiol. 2021; ()
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
Lancet Diabetes Endocrinol. 2021; 9: 293-303
Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?.
J Diabetes Complications. 2020; 34107723
Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.
Biochem Biophys Res Commun. 2020; 524: 332-339
Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.
Ther Adv Endocrinol Metab. 2021; 12 ()
Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19.
Diabetes Metab J. 2021; 45: 251-259
Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.
Lancet Reg Health Eur. 2021; ()
Diabetes, obesity, COVID-19, Insulin, and other antidiabetes drugs.
Diabetes Care. 2021; 44: 1929-1933
Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes.
Cell Metab. 2021; 33: 65-77
Renin-angiotensin-aldosterone system blockers and the risk of COVID-19.
N Engl J Med. 2020; 382: 2431-2440
Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19).
JAMA Cardiol. 2020; 5: 1020-1026
Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19.
Circ Res. 2020; 126: 1671-1681
The plasmatic aldosterone and c-reactive protein levels, and the severity of COVID-19: the Dyhor-19 study.
J Clin Med. 2020; 9E2315
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
Cell. 2020; 181: 271-280.e8
Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.
Cell. 2020; 181: 281-292.e6
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Science. 2021; 372eabg3055
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.
Science. 2021; 372: 815-821
Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020.
Euro Surveill. 2021; 262002106
Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data.
J Cell Physiol. 2021; 236: 7045-7057
Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein.
Heliyon. 2021; 7e06564
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Nature. 2020; 581: 215-220
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
Science. 2020; 370: 856-860
Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection.
Cell. 2021; 184: 76-91
Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes.
Cell. 2021; 184: 149-168
Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19.
Crit Care. 2020; 24: 484
Regulated cell death and inflammation: an auto-amplification loop causes organ failure.
Nat Rev Immunol. 2014; 14: 759-767
The MERS-CoV Receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike.
iScience. 2020; 23101160
Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Crit Rev Clin Lab Sci. 2003; 40: 209-294
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Endocr Rev. 2014; 35: 992-1019
Coronavirus Infections and type 2 diabetes-shared pathways with therapeutic implications.
Endocr Rev. 2020; 41bnaa011
The impact of obesity on severe disease and mortality in people with SARS-CoV-2: a systematic review and meta-analysis.
Endocrinol Diabetes Metab. 2020; 4e00176
A metabolic handbook for the COVID-19 pandemic.
Nat Metab. 2020; 2: 572-585
Causes, consequences, and treatment of metabolically unhealthy fat distribution.
Lancet Diabetes Endocrinol. 2020; 8: 616-627
COVID-19 and the heart.
Circ Res. 2020; 126: 1443-1455
COVID-19 presenting as stroke.
Brain Behav Immun. 2020; 87: 115-119
Insulin receptor signaling in normal and insulin-resistant states.
Cold Spring Harb Perspect Biol. 2014; 6a009191
How the association between obesity and inflammation may lead to insulin resistance and cancer.
Diabetes Metab Syndr. 2019; 13: 1213-1224
Macrophage function in obesity-induced inflammation and insulin resistance.
Pflugers Arch. 2017; 469: 385-396
Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications.
Diabetol Metab Syndr. 2021; 13: 23
Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation.
PLoS One. 2015; 10e0133494
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.
Diabetes Res Clin Pract. 2014; 105: 141-150
Blood sugar regulation for cardiovascular health promotion and disease prevention: JACC health promotion series.
J Am Coll Cardiol. 2018; 72: 1829-1844
Regulation of adrenocortical function by cytokines–relevance for immune-endocrine interaction.
Horm Metab Res. 1998; 30: 416-420
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis.
Mol Psychiatry. 2020; 25: 1611-1617
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Lancet Respir Med. 2021; 9: 763-772
Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection.
Lancet Diabetes Endocrinol. 2020; 8: 472-473
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
J Biol Regul Homeost Agents. 2020; 34: 327-331
Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: case series.
Curr Ther Res Clin Exp. 2020; 93100609
Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection.
Am J Emerg Med. 2020; 38: 2491e3-2491e4
Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report.
Nat Metab. 2020; 2: 1021-1024
COVID-19 infection may cause ketosis and ketoacidosis.
Diabetes Obes Metab. 2020; 22: 1935-1941
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.
Nat Metab. 2021; 3: 774-785
New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19.
J Pediatr Endocrinol Metab. 2020; 34: 147-150
New-onset diabetes in COVID-19.
N Engl J Med. 2020; 383: 789-790
Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany.
JAMA. 2020; 324: 801-804
New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic.
Arch Dis Child. 2021; ()
Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP).
BMJ Case Rep. 2020; 13e237903
Can COVID-19 cause diabetes?.
Nat Metab. 2021; 3: 123-125
Adhering to COVID-19 health guidelines: examining demographic and psychological predictors of adherence.
Appl Psychol Health Well-Being. 2021; ()
COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges.
Diabetes Metab Syndr. 2021; 15: 505-508
The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation.
Diabetologia. 2021; 64: 1184-1186
The European perspective of diabetes prevention: the need for individualization of diabetes prevention.
J Endocrinol Invest. 2013; 36: 352-357
Diabetes management during coronavirus.
Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic.
Diabet Med. 2021; 38e14469
Diabetes-related amputations: a pandemic within a pandemic.
J Am Podiatr Med Assoc. 2020; ()
Serum hypoglycemia.
Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals.
Diabetes Metab Syndr. 2020; 14: 965-967
The impact of COVID-19 restrictions on accelerometer-assessed physical activity and sleep in individuals with type 2 diabetes.
Diabet Med. 2021; ()
Diabetes and COVID-19: population impact 18 months into the pandemic.
Diabetes Care. 2021; 44: 1916-1923
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.
Lancet Diabetes Endocrinol. 2021; 9: 82-93
A post COVID-19 ‘Marshall Plan’ for type 2 diabetes.
Diabet Med. 2021; 38e14439
Psychological crisis intervention for COVID-19 lockdown stress in patients with type 1 diabetes mellitus: survey study and qualitative analysis.
JMIR Ment Health. 2021; 8e28097
Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic.
BMJ Open Diabetes Res Care. 2021; 9e002035
Stress and physical inactivity: two explosive ingredients for the heart in COVID-19 pandemic times.
Curr Cardiol Rev. 2021; ()
Pharmacological management of COVID-19 in type 2 diabetes.
J Diabetes Complications. 2021; 35107927
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Diabetes Endocrinol. 2021; 9: 586-594
Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study.
Diabetes Res Clin Pract. 2021; 175108695
Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes.
Diabetes Care. 2021; 44: e64-e66
Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and covid-19: a multicenter, case-control, retrospective, observational study.
Diabetes Care. 2020; 43: 2999-3006
Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis.
J Med Virol. 2021; 93: 695-697
Metformin and COVID-19: from cellular mechanisms to reduced mortality.
Diabetes Metab. 2020; 46: 423-426
Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes.
Cell Metab. 2020; 32: 537-547
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet. 2021; 397: 1637-1645
Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis.
Clin Exp Rheumatol. 2019; 37: 465-473
Negative impact of hyperglycaemia on tocilizumab therapy in COVID-19 patients.
Diabetes Metab. 2020; 46: 403-405
Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.
Diabetologia. 2020; 63: 1440-1452
Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: meta-analysis A.
JAMA. 2020; 324: 1330-1341
Glucocorticoid-induced hyperglycemia.
J Diabetes. 2014; 6: 9-20
FDA expands remote patient monitoring in hospitals for people with diabetes during COVID-19; manufacturers donate CGM supplies.
Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes.
Cell Metab. 2020; 31: 1068-1077
Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis.
Diabetes Care. 2021; 44: 578-585
Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study.
Diabetes Care. 2021; 44: 549-555
Altered lipid metabolism in recovered SARS patients twelve years after infection.
Sci Rep. 2017; 79110
Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes.
Acta Diabetol. 2010; 47: 193-199
Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study.
BMC Neurol. 2011; 11: 37
COVID-19 and chronic fatigue syndrome: is the worst yet to come?.
Med Hypotheses. 2021; 146110469
High-dimensional characterization of post-acute sequelae of COVID-19.
Nature. 2021; 594: 259-264
The Stanford Hall consensus statement for post-COVID-19 rehabilitation.
Br J Sports Med. 2020; 54: 949-959
The adrenal gland in stress – adaptation on a cellular level.
J Steroid Biochem Mol Biol. 2019; 190: 198-206
Experiences, opinions and expectations of health care providers towards an intensive care unit follow-up clinic: Qualitative study and online survey.
Intensive Crit Care Nurs. 2021; ()
Mucormycosis.
Infect Dis Clin North Am. 2021; 35: 435-452
Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum.
J Laryngol Otol. 2021; 135: 442-447
Long COVID – metabolic risk factors and novel therapeutic management.
Nat Rev Endocrinol. 2021; 17: 379-380
Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study.
BMJ. 2021; 372: n693
Prevalence of people at risk of developing type 2 diabetes mellitus and the involvement of community pharmacies in a national screening campaign: a pioneer action in Brazil.
Diabetol Metab Syndr. 2020; 12: 89
Diabetes mellitus in India: the modern scourge.
Med J Armed Forces India. 2009; 65: 50-54
Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults.
Eur J Epidemiol. 2013; 28: 169-180
Coronavirus in Africa: five reasons why COVID-19 has been less deadly than elsewhere.
What should governments be doing to prevent diabetes throughout the life course?.
Diabetologia. 2019; 62: 1842-1853
Digital health surveillance strategies for management of coronavirus disease 2019.
Mayo Clin Proc Innov Qual Outcomes. 2021; 5: 109-117
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Trials. 2021; 22: 39
A quantitative estimation of the pancreatic islet tissue1.
QJM. 1937; 6: 287-300
Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
Diabetes Obes Metab. 2021; 23: 910-915
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Lancet. 2021; 396: 2019-2082
|
Sources 2/ https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00244-8/fulltext The mention sources can contact us to remove/changing this article |
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]
 |
 |
 |
